MindBio Therapeutics reposted this
Everything you missed in #Pharma & #Biotech 🦠🔬 ✅ Approvals FDA approves Johnson & Johnson’s Rybrevant (amivantamab-vmjw) in combination with Lazcluze (lazertinib) as a first-line, chemotherapy-free treatment for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) AstraZeneca's Imfinzi (durvalumab) approved by the FDA for treatment of resectable NSCLC used alongside chemotherapy before surgery and as monotherapy after surgery Moderna receives European Commission approval for RSV vaccine mRESVIA (mRNA-1345) to protect adults aged 60 and older against respiratory syncytial virus (RSV) infections Biogen, Eisai US’s Leqembi approved by MHRA in the UK despite refusal by EMA in July 2024 FDA approves Vericel® Corporation's less invasive knee repair product MACI Arthro and NexoBrid for pedicatric burns 💸 Deals Johnson & Johnson to acquire Israeli medtech V-Wave, a heart failure device maker GondolaBio, a BridgeBio Pharma spinout, launches with $300 million to develop rare disease drugs Bicara Therapeutics and Zenas BioPharma file for IPOs to advance late-stage cancer and autoimmune drug candidates Alzamend Neuro partners with Mass General for Ph2 Alzheimer’s treatment trial Together Women's Health partners with digital care delivery platform true. Women's Health’s to enhance access to personalized menopause care Cyclo Therapeutics, Inc. completes merger with Rafael Holdings, Inc., boosting its financial backing to accelerate late-stage trials Israel-based pharmaceutical company SciSparc to outlicense SCI-160 programme for pain treatment to Polyrizon Ltd. Pathos expands pipeline with worldwide license of Prelude Therapeutics' Phase 2-ready brain-penetrant PRMT5 inhibitor, aimed at treating CSN diseases including glioblastoma 🎯Late-stage developments CANbridge Pharmaceuticals Inc. announces positive topline results from its pivotal CAN103 trial for Gaucher disease in China, plans NDA Filing in Q4 2024 Incyte announces positive topline results from pivotal study of Tafasitamab (Monjuvi) in relapsed or refractory follicular lymphoma 📈 Access NICE deems Eisai US's Alzheimer's drug Leqembi (lecanemab) not cost-effective for NHS use due to high costs and limited patient benefits Theramex’s Eladynos (abaloparatide) to be available for menopausal women with osteoporosis in England following positive guidance from NICE ✳️ Other The National Institutes of Health launches $3M prize competition to innovate endometriosis diagnostics MindBio Therapeutics’s LSD-based drug MB22001 reduces depression symptoms in Phase IIa trial Neptune Medical raises $97 million to launch its Jupiter endovascular robotics platform Medtech venture capital investment remained steady in Q2 2024, with $3.3 billion in deal value, according to PitchBook data 👉 What’s your favorite industry news? #pharma #biotech #pulsenews #curiousminds #techbio Hannah Kurth Patricia Machado Tamsin Lacourte Alexandra SILVAIN
